Post progression survival in glioblastoma: where are we?

Franceschi, Enrico; Ermani, Mario; Bartolini, Stefania; Bartolotti, Marco; Poggi, Rosalba; Tallini, Giovanni; Marucci, Gianluca; Fioravanti, Antonio; Tosoni, Alicia; Agati, Raffaele; Bacci, Antonella; Pozzati, Eugenio; Morandi, Luca; Balestrini, Damiano; Ghimenton, Claudio; Crisi, Girolamo; Brandes, Alba
January 2015
Journal of Neuro-Oncology;Jan2015, Vol. 121 Issue 2, p399
Academic Journal
The optimal end point for phase II studies for recurrent glioblastoma (GBM) is unclear and a matter of debate. Moreover, data about post-progression survival (PPS) after the first disease progression in GBM patients treated according to EORTC 26981/22981/NCIC CE.3 trial are limited. The aim of this study was to evaluate the PPS in GBM patients. The analysis was made with a database on 1,006 GBM patients followed prospectively between 06/2005 and 06/2010. Eligibility criteria for the study were: age ≥18 years; PS: 0-2; chemotherapy given at disease progression after RT/TMZ. 232 patients (mean age 52 years, range 18-77 years) were enrolled. The median PFS following second line chemotherapy (PFS2) was 2.5 months (95 % CI 2.1-2.9) and the rate of patients free of progression at 6 months (PFS2-6 mo), was 21.6 % (95 % CI 16.3-26.9 %). The median PPS was 8.6 months (95 % CI 7.4-9.8), PPS rates were: PPS-6: 66 % (95 % CI 60.3-72.9 %), PPS-9: 48.2 % (95 % CI 41.5-54.9 %) and PPS-12: 31.7 % (95 % CI 25.2-38.2 %). PPS in unselected patients treated with alkylating agents is about 8 months. PPS rates could be of interest as an end point in future studies in recurrent GBM.


Related Articles

  • Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution. Azoulay, Melissa; Santos, Fabiano; Souhami, Luis; Panet-Raymond, Valerie; Petrecca, Kevin; Owen, Scott; Guiot, Marie-Christine; Patyka, Mariia; Sabri, Siham; Shenouda, George; Abdulkarim, Bassam // Radiation Oncology;2015, Vol. 10 Issue 1, p1 

    Background: The optimal fractionation schedule of radiotherapy (RT) for Glioblastoma multiforme (GBM) is yet to be determined. We aim to compare different fractionation regimens and identify prognostic factors to better tailor RT for newly diagnosed GBM patients. Methods: All data for patients...

  • Medical therapy of gliomas. Ahluwalia, Manmeet; Chang, Susan // Journal of Neuro-Oncology;Sep2014, Vol. 119 Issue 3, p503 

    Medical therapies are an important part of adjunctive therapy for gliomas. In this chapter we will review the chemotherapeutic and targeted agents that have been evaluated in clinical trials in grade II-IV gliomas in the last decade. A number of randomized phase III trials were completed and...

  • Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. Eisele, Günter; Wick, Antje; Eisele, Anna-Carina; Clément, Paul; Tonn, Jörg; Tabatabai, Ghazaleh; Ochsenbein, Adrian; Schlegel, Uwe; Neyns, Bart; Krex, Dietmar; Simon, Matthias; Nikkhah, Guido; Picard, Martin; Stupp, Roger; Wick, Wolfgang; Weller, Michael // Journal of Neuro-Oncology;Mar2014, Vol. 117 Issue 1, p141 

    The integrin antagonist cilengitide has been explored as an adjunct with anti-angiogenic properties to standard of care temozolomide chemoradiotherapy (TMZ/RT → TMZ) in newly diagnosed glioblastoma. Preclinical data as well as anecdotal clinical observations indicate that anti-angiogenic...

  • Extracranial glioblastoma with synchronous metastases in the lung, pulmonary lymph nodes, vertebrae, cervical muscles and epidural space in a young patient - case report and review of literature. Blume, Christian; Lehe, Marec von; Landeghem, Frank van; Greschus, Susanne; Boström, Jan // BMC Research Notes;2013, Vol. 6 Issue 1, p1 

    Background: Extraneural and extracranial metastases of glioblastoma (GB) are very rarely reported in the literature. They occur in only 0.2% of all GB patients. Case presentation: We present a 40 year old caucasian male with secondary GB and first diagnosis of an astrocytoma world health...

  • Hypofractionated stereotactic reirradiation for recurrent glioblastoma. Yazici, Gozde; Cengiz, Mustafa; Ozyigit, Gokhan; Eren, Gulnihan; Yildiz, Ferah; Akyol, Fadil; Gurkaynak, Murat; Zorlu, Faruk // Journal of Neuro-Oncology;Oct2014, Vol. 120 Issue 1, p117 

    Treatment choices for recurrent glioblastoma patients are sparse and the results are not satisfactory. In this retrospective analysis, we evaluated the results of re-irradiation of locally recurrent glioblastoma patients with an image-guided, fractionated, frameless stereotactic radiotherapy...

  • How surgery, radiotherapy and chemotherapy each contribute to the outcome of treatment for adult patients with Glioblastoma? Rojas Villabona, Álvaro // Revista Médicas UIS;2012, Vol. 25 Issue 3, p209 

    Introduction: glioblastoma is a common condition associated with high morbidity and mortality; most of newly diagnosed patients will die within two years. The current standard therapy is maximal surgical resection followed by radiotherapy plus concomitant and adjuvant temozolamide. Objective: it...

  • 'Elderly' patients with newly diagnosed glioblastoma deserve optimal care. Holdhoff, Matthias; Rosner, Gary; Alcorn, Sara; Grossman, Stuart // Journal of Neuro-Oncology;Jul2013, Vol. 113 Issue 2, p343 

    No abstract available.

  • Extended Daily Schedule of Temozolomide in Recurrent Glioblastoma: Single-Institution Report on a Series of 43 Patients. D'Elia, Alessandro; Maiola, Vincenza; Manucci, Mirena; Pichierri, Angelo; Frati, Alessandro; Giangaspero, Felice; Salvati, Maurizio // Journal of Cancer Therapy;Feb2014, Vol. 5 Issue 5, p155 

    Background: Despite advances in surgical and first-line adjuvant treatment, glioblastoma multiforme (GBM) always recurs as disease natural history. Currently, there is no consensus as to the optimal second-line treatment of recurrent GBM. Patients and Methods: This is a retrospective study of a...

  • NeoPharm reaches agreement with FDA on phase III "Precise" trial.  // PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p20 

    Reports that NeoPharm Inc. reached an agreement with the Food and Drug Administration regarding its Precise trial designed to be a study of the company's experimental tumor-targeting, anticancer drug IL13-PE38QQR, that is being investigated as a treatment for first recurrence of glioblastoma...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics